Comparison between metformin and intermittent fasting for renoprotective effects through mitophagy modulation in a rat cisplatin-induced acute kidney injury model
Abstract
Abstract The current study investigated the effects of metformin versus intermittent fasting as modulators of mitophagy in cisplatin-induced acute renal injury in rats. Twenty-four adult male rats were divided into four groups: control, cisplatin, metformin-treated, and intermittent fasting groups. Cisplatin (8 mg/kg, intraperitoneal) was administered once on day eight, while metformin (200 mg/kg) was given orally for 12 days. Renal function parameters including serum creatinine, blood urea nitrogen (BUN), fractional excretion of sodium (FENa), and serum sodium and potassium levels were measured, along with urinary NGAL and renal oxidative stress markers (MDA and SOD). Mitophagy was assessed by immunohistochemical evaluation of LC3 and p62 expression, measurement of PINK1 levels, and Parkin gene expression, in addition to histopathological examination of renal tissues. Cisplatin administration significantly impaired kidney function, increased oxidative stress and p62 expression, and reduced SOD, LC3, PINK1, and Parkin gene expression, accompanied by marked histopathological renal damage. Treatment with metformin or intermittent fasting significantly improved renal function tests, reduced oxidative stress and p62 levels, and restored LC3, PINK1, and Parkin expression, with corresponding improvement in renal histopathology. These findings suggest that metformin and intermittent fasting exert protective effects against cisplatin-induced acute kidney injury, potentially through…
How strong is the evidence?
Evidence Hub reads this as a preprint, done in animal, not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.